Gelonghui May 22丨Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK) issued an announcement. Recently, Xinhua Pharmaceutical received the “Drug Registration Certificate” for escitalopram oxalate tablets (10mg) approved and issued by the State Drug Administration.

According to the disclosure, escitalopram oxalate tablets are a single dextro-optical isomer of racecitalopram, a dicyclic hydrophthalate derivative, used to treat depression and panic disorder with or without agoraphobia. Compared with similar antidepressants, escitalopram oxalate tablets have better efficacy and acceptability, and are a first-line treatment for depression.